- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Sex hormone-binding globulin.
Displaying page 1 of 2.
EudraCT Number: 2007-006082-32 | Sponsor Protocol Number: 2293/2007 | Start Date*: 2007-12-13 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA PISANA | |||||||||||||
Full Title: Female steroid hormones and protection from cardiovascular risk: staminal endothelial progenitor cells and menopause. | |||||||||||||
Medical condition: Postmenopause | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004163-39 | Sponsor Protocol Number: HSJD-LIT-05 | Start Date*: 2005-11-14 |
Sponsor Name:Hospital Sant Joan de Déu | ||
Full Title: Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism ... | ||
Medical condition: Polycystic Ovary Syndrome includes anovulatory hyperandrogenism, hyperinsulinemia and/or dyslipidemia. Adiponectin and interleukin-6 are adipocytokines that have been related to abdominal fat exces... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000573-72 | Sponsor Protocol Number: ATOS-010 | Start Date*: 2018-04-21 |
Sponsor Name:Atossa Genetics Inc | ||
Full Title: Karma CREME-1: A double-blind, placebo-controlled, three-armed, pilot study of the effects, safety and tolerability of topical endoxifen in women within the Karma Cohort | ||
Medical condition: The mammographic density reduction in healthy women. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002906-10 | Sponsor Protocol Number: BHR-700-301 | Start Date*: 2018-08-16 | |||||||||||
Sponsor Name:BHR Pharma, LLC | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women with BI-RADS Breast Density Categories C or D | |||||||||||||
Medical condition: Breast tissue density in women with BI-RADS Breast Density Categories C to D | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001614-13 | Sponsor Protocol Number: 301886 | Start Date*: 2005-06-08 |
Sponsor Name:Schering AG | ||
Full Title: A single-center, open-label, controlled, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) as compared to a seq... | ||
Medical condition: Contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002409-21 | Sponsor Protocol Number: 358 | Start Date*: 2005-11-09 |
Sponsor Name:Population Council - Center for Biomedical Research | ||
Full Title: A dose-finding randomized clinical trial to evaluate the differential impact of four progestins for their use as male contraceptives in healthy men. | ||
Medical condition: This clinical trial tests several products for their future usefulness for male contraception. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019865-26 | Sponsor Protocol Number: ES-CO2 | Start Date*: 2010-07-15 | |||||||||||
Sponsor Name:Estetra S.A. | |||||||||||||
Full Title: A randomised, open-label, multi-centre, dose-finding study to evaluate cycle control of 15 mg or 20 mg estetrol combined with either 150 μg levonorgestrel or 3 mg drospirenone, compared to a combin... | |||||||||||||
Medical condition: Only healthy premenopausal volunteers will participate in this clinical trial. Intended indication: contraception. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001624-17 | Sponsor Protocol Number: 210321 | Start Date*: 2021-07-21 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Prog... | ||
Medical condition: Climacteric symptoms | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001478-78 | Sponsor Protocol Number: MCT8-2021-3 | Start Date*: 2023-03-31 |
Sponsor Name:Rare Thyroid Therapeutics International AB | ||
Full Title: Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double blind, Randomized, Placebo controlled Study | ||
Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency | ||
Disease: | ||
Population Age: Children, Under 18, Adults | Gender: Male | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002602-78 | Sponsor Protocol Number: DSG-HSP-201 | Start Date*: 2011-09-21 | |||||||||||
Sponsor Name:Teva Women's Health Research&Development, a division of Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women | |||||||||||||
Medical condition: The impact of an experimental birth control drug on hemostatic parameters (characteristics of the blood) compared to a standard marketed birth control pill in healthy women (contraceptive) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003002-27 | Sponsor Protocol Number: MIT-Es001-C303 | Start Date*: 2020-10-14 | |||||||||||
Sponsor Name:Estetra SRL | |||||||||||||
Full Title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate an... | |||||||||||||
Medical condition: Contraception | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: FI (Completed) EE (Completed) LV (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000041-12 | Sponsor Protocol Number: 49/11/EDG/TP2 | Start Date*: 2012-03-23 | |||||||||||
Sponsor Name:Zentiva k.s. Prague | |||||||||||||
Full Title: Characterisation of ovulation inhibition and effects on metabolic parameters and haemostatic system of multiple administrations of a fixed-dose combination product containing 0.02 mg ethinylestradi... | |||||||||||||
Medical condition: Investigation of ovulation inhibition, effects on metabolic parameters and haemostatic system for indication of contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001373-16 | Sponsor Protocol Number: CLIK066X2205 | Start Date*: 2017-09-04 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, subject- and investigator-blinded, placebo-controlled pharmacodynamic study of oral LIK066 in overweight and obese women with polycystic ovary syndrome | |||||||||||||
Medical condition: polycystic ovary syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001162-10 | Sponsor Protocol Number: EUOG2014-002 | Start Date*: 2015-05-06 | |||||||||||
Sponsor Name:European Uro- Oncology Group (EUOG) | |||||||||||||
Full Title: An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Hormono-Naïve patients with Metastatic Prostate ... | |||||||||||||
Medical condition: Patients with Metastatic Prostate Cancer who have never been treated with Androgen Deprivation Therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001161-27 | Sponsor Protocol Number: EUOG2014-001 | Start Date*: 2015-05-18 | |||||||||||
Sponsor Name:European Uro- Oncology Group (EUOG) | |||||||||||||
Full Title: An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Chemo-Naïve patients with Progressive Prostate C... | |||||||||||||
Medical condition: Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001545-15 | Sponsor Protocol Number: 307720 | Start Date*: 2004-11-04 |
Sponsor Name:Schering AG | ||
Full Title: Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo de Testogel® (testosterona 50–100mg) para evaluar su eficacia y seguridad en hombres que presentan síntomas típicos de defic... | ||
Medical condition: Déficit Androgénico parcial en la edad avanzada. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000633-36 | Sponsor Protocol Number: 000009 | Start Date*: 2011-08-09 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, controlled, assessor-blind, parallel groups, multinational, multicentre trial assessing the dose-response relationship of FE 999049 in controlled ovarian stimulation in women undergoi... | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) BE (Completed) CZ (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021287-16 | Sponsor Protocol Number: 9785-CL-0321 | Start Date*: 2010-11-29 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer | |||||||||||||
Medical condition: Hormone-naïve prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) DE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000099-27 | Sponsor Protocol Number: HEAT01 | Start Date*: 2017-04-26 | |||||||||||
Sponsor Name:The Department of Urology | |||||||||||||
Full Title: Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial | |||||||||||||
Medical condition: Metastisc castration resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003630-33 | Sponsor Protocol Number: ERGO45359 | Start Date*: 2019-01-23 | |||||||||||
Sponsor Name:University of Southampton | |||||||||||||
Full Title: Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe p... | |||||||||||||
Medical condition: Acne of sufficient severity to warrant treatment with oral antibiotics. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
